Diagnostic procedures and therapeutic strategies in fungal invasive infections in immunocompromised patients;Démarche diagnostique et prise en charge des infections fongiques chez les patients immunodéprimés

Antibiotiques

Volumn 9, Issue 1, 2007, Pages 34-43

  Botterel, F ^a  

^a HENRI MONDOR HOSPITAL   (France)

Author keywords

Diagnostics; Invasive aspergillosis; Invasive candidiasis; Therapeutic antifungal strategies

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; BETA GLUCAN; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; LIPOSOME; NOLFATIL; POSACONAZOLE; UNCLASSIFIED DRUG; VORICONAZOLE;

ASPERGILLOSIS; ASPERGILLUS; CANDIDA; CLINICAL RESEARCH; DIAGNOSTIC PROCEDURE; DRUG FORMULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EVALUATION; FUNGAL STRAIN; HUMAN; IMMUNE DEFICIENCY; IN VITRO STUDY; MOLECULE; MYCOSIS; ORGANIZATION AND MANAGEMENT; REVIEW; SCIENTIFIC LITERATURE; TREATMENT INDICATION; YEAST;

EID: 33847128299     PISSN: 12945501     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1294-5501(07)88765-6     Document Type: Article

References (43)

1. GUDLAUGSSON O, GILLESPIE S, LEE K et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003 ; 37(9) : 1172-7.
2. LIN SJ, SCHRANZ J, TEUTSCH SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001 ; 32(3) : 358-66.
3. ASCIOGLU S, REX JH, DE PAUW B et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002 ; 34 : 7-14.
4. Conférence de consensus. Prise en charge des candidoses et aspergilloses invasives de l'adulte. J Mycol Med 2004 ; 14 : 142-6.
5. OSTROSKY-ZEICHNER L, PAPPAS PG. Invasive candidiasis in the intensive care unit. Crit Care Med 2006 ; 34(3) : 857-63.
6. ARCHIBALD LK, MCDONALD LC, ADDISON RM et al. Comparison of BACTEC MYCO/F LYTIC and WAMPOLE ISOLATOR 10 (lysis-centrifugation) systems for detection of bacteremia, mycobacteremia, and fungemia in a developing country. J Clin Microbiol 2000 ; 38(8) : 2994-7.
7. PIARROUX R, GRENOUILLET F, BALVAY P et al. Assessment of preemptive treatment to prevent severe candidiasis in critically ill surgical patients. Crit Care Med 2004 ; 32(12) : 2443-9.
8. STEPHAN F, BAH MS, DESTERKE C et al. Molecular diversity and routes of colonization of Candida albicans in a surgical intensive care unit, as studied using microsatellite markers. Clin Infect Dis 2002 ; 35 : 1477-83.
9. SENDID B, POIROT JL, TABOURET M et al. Combined detection of mannanaemia and antimannan antibodies as a strategy for the diagnosis of systemic infection caused by pathogenic Candida species. J Med Microbiol 2002 ; 51(5) : 433-42.
10. YEO SF, WONG B. Current status of nonculture methods for diagnosis of invasive fungal infections. Clin Microbiol Rev 2002 ; 15 : 465-484.
11. CAILLOT D, COUAILLIER JF, BERNARD A et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol 2001 ; 19(1) : 253-9.
12. STYNEN D, GORIS A, SARFATI J et al. A new sensitive sandwich enzyme-linked immunosorbent assay to detect galactofuran in patients with invasive aspergillosis. J Clin Microbiol 1995 ; 33 : 497-500.
13. MAERTENS J, VERHAEGEN J, DEMUYNCK H et al. Autopsy-controlled prospective evaluation of serial screening for circulating galactomannan by a sandwich enzyme-linked immunosorbent assay for hematological patients at risk for invasive Aspergillosis. J Clin Microbiol 1999 ; 37 : 3223-8.
14. BRETAGNE S, MARMORAT-KHUONG A, KUENTZ M et al. Serum Aspergillus galactomannan antigen testing by sandwich ELISA: practical use in neutropenic patients. J Infect 1997 ; 35 : 7-15.
15. AUBRY A, PORCHER R, BOTTERO J et al. Occurrence and kinetics of false-positive Aspergillus galactomannan test results following treatment with beta-lactam antibiotics in patients with hematological disorders. J Clin Microbiol 2006 ; 44(2) : 389-94.
16. OSTROSKY-ZEICHNER L, ALEXANDER BD, KETT DH et al. Multicenter clinical evaluation of the (1 - >3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 2005 ; 41(5) : 654-9.
17. BRETAGNE S, COSTA JM, BART-DELABESSE E et al. Comparison of serum galactomannan antigen detection and competitive polymerase chain reaction in diagnosing invasive aspergillosis. Clin Inf Dis 1998 ; 26 : 1407-12.
18. HEBART H, LOFFLER J, MEISNER C et al. Early detection of Aspergillus infection after allogeneic stem cell transplantation by polymerase chain reaction screening. J Infect Dis 2000 ; 181 : 1713-19.
19. CHEN SC, HALLIDAY CL, MEYER W. A review of nucleic acid-based diagnostic tests for systemic mycoses with an emphasis on polymerase chain reaction-based assays. Med Mycol 2002 ; 40 : 333-57.
20. COSTA C, VIDAUD D, OLIVI M et al. Development of two real-time quantitative TaqMan PCR assays to detect circulating Aspergillus fumigatus DNA in serum. J Microbiol Methods 2001 ; 44 : 263-9.
21. COSTA C, COSTA JM, DESTERKE C et al. Realtime PCR coupled with automated DNA extraction and detection of galactomannan antigen in serum by enzyme-linked immunosorbent assay for diagnosis of invasive aspergillosis. J Clin Microbiol 2002 ; 40 : 2224-7.
22. LOEFFLER J, HENKE N, HEBART H et al. Quantification of fungal DNA by using fluorescence resonance energy transfer and the light cycler system. J Clin Microbiol 2000 ; 38 : 586-90.
23. KAMI M, FUKUI T, OGAWA S et al. Use of real-time PCR on blood samples for diagnosis of invasive aspergillosis. Clin Infect Dis 2001 ; 33 : 1504-12.
24. REX JH, WALSH TJ, SOBEL JD et al. Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America. Clin Infect Dis 2000 ; 30 : 662-78.
25. ALFANDARI S, LEROY O, DE BOTTON S et al. Groupe de travail du CHRU de Lille. [Management of aspergillosis in immuno-compromised patients. Recommendations of Lille University Hospital - 4th version - November 2004]. Med Mal Infect 2005 ; 35(3) : 121-34.
26. OUDE LASHOF AM, DONNELLY JP, MEIS JF et al. Duration of antifungal treatment and development of delayed complications in patients with candidaemia. Eur J Clin Microbiol Infect Dis 2003 ; 22(1) : 43-8.
27. FLEMING RV, KANTARJIAN HM, HUSNI R et al. Comparison of amphotericin B lipid complex (ABLC) vs. ambisome in the treatment of suspected or documented fungal infections in patients with leukemia. Leuk Lymphoma 2001 ; 40(5-6) : 511-20.
28. WALSH TJ, FINBERG RW, ARNDT C et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med 1999 ; 340 : 764-71.
29. WALSH TJ, PAPPAS P, WINSTON DJ et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002 ; 346 : 225-34.
30. HERBRECHT R, DENNING DW, PATTERSON TF et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Eng J Med 2002 ; 347 : 408-15.
31. SMITH J, SAFDAR N, KNASINSKI V et al. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother 2006 ; 50(4) : 1570-2.
32. TORRES HA, HACHEM RY, CHEMALY RF et al. Posaconazole: a broad spectrum triazole antifungal. Lancet Infect Dis 2005 ;5(12) : 775-85.
33. ARATHOON EG, GOTUZZO E et al. Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases. Antimicrob Agents Chemother 2002 ; 46 : 451-7.
34. MORA-DUARTE J, ROBERT BETTS R, LOPES COLOMBO A et al. Comparison of Caspofungin and Amphotericin B for Invasive Candidiasis. N Eng J Med 2002 ; 347 : 2020-9.
35. WINGARD JR, WHITE MH, ANAISSIE E et al. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. Clin Infect Dis 2000 ; 31(5) : 1155-63.
36. WALSH TJ, PAPPAS P, WINSTON DJ et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med. 2002 ; 346(4) : 225-34.
37. ARIKAN S, LOZANO-CHIU M, PAETZNICK V et al. In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. J Clin Microbiol 2002 ; 40(4) : 1406-12.
38. MANAVATHU EK, ALANGADEN GJ, CHANDRASEKAR PH. Differential activity of triazoles in two-drug combinations against Aspergillus fumigatus. J Antimicrob Chemother 2003 ; 51(6) : 1423-5.
39. NAJVAR LK, CACCIAPUOTI A, HERNANDEZ S et al. Activity of posaconazole combined with amphotericin B against Aspergillus flavus infection in mice: comparative studies in two laboratories. Antimicrob Agents Chemother 2004 ; 48(3) : 758-64.
40. SINGH N, LIMAYE AP, FORREST G et al. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation 2006 ; 81(3) : 320-6.
41. YEGHEN T, KIBBLER CC, PRENTICE HG et al. Management of invasive pulmonary aspergillosis in hematology patients: a review of 87 consecutive cases at a single institution. Clin Infect Dis 2000 ; 31(4) : 859-68.
42. BERNARD A, CAILLOT D, COUAILLIER JF et al. Surgical management of invasive pulmonary aspergillosis in neutropenic patients. Ann Thorac Surg 1997 ; 64(5) : 1441-7.
43. JOHNSON MD, KLEINBERG M, DANZIGER L et al. Pharmacoeconomics of antifungal pharmacotherapy-challenges and future directions. Expert Opin Pharmacother 2005 ; 6(15) : 2617-32.